<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2721">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435353</url>
  </required_header>
  <id_info>
    <org_study_id>AstanaMU</org_study_id>
    <nct_id>NCT04435353</nct_id>
  </id_info>
  <brief_title>Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19</brief_title>
  <official_title>Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astana Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astana Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vibroacoustic pulmonary therapy in patients with COVID19 is believed to have a positive
      effect on oxygen status and a decrease in the duration of respiratory failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to recruit the required number of patients for statistical identification of
      the effectiveness of vibroacoustic therapy in patients with COVID 19. Obligatory performance
      criteria will be presented by the duration of the course of respiratory failure and the
      duration of mechanical ventilation in the main and control groups. Optional performance
      criteria will be represented by oximetry values and standardization of laboratory parameters
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective\retrospective study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Research involves single blinding (researcher statistician)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery respiratory fail</measure>
    <time_frame>5-7 days</time_frame>
    <description>Regression of respiratory failure under the influence of vibroacoustic therapy</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>Time-day of respiratory fail</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Objective data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen status</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Facultative data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxugen support</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FiO2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adverse outcomes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Complication</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VibroLUNG</intervention_name>
    <description>Lungs intensive therapy</description>
    <arm_group_label>Adverse outcomes</arm_group_label>
    <arm_group_label>Oxugen support</arm_group_label>
    <arm_group_label>Oxygen status</arm_group_label>
    <arm_group_label>Time-day of respiratory fail</arm_group_label>
    <other_name>Vibroacustic device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. adults

          2. P/F less 300 torr

          3. ARDS by Berlin convention

          4. COVID 19 bilateral pneumonia

        Exclusion Criteria:

          1. children

          2. acute brain stroke

          3. acute coronary syndrome

          4. pulmonary embolism

          5. implanted pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irina Mukatova, PhD</last_name>
    <phone>8701 535 96 79</phone>
    <email>mukatovair@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mukatova Irina</name>
      <address>
        <city>Astana</city>
        <state>Nur-Sultan</state>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Mukatova, MD</last_name>
      <phone>8701 535 96 79</phone>
      <email>mukatovair@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center of pulmonology Astana</name>
      <address>
        <city>Astana</city>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Vahrushev, Dr</last_name>
      <phone>8701 196 92 68</phone>
    </contact>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 14, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Astana Medical University</investigator_affiliation>
    <investigator_full_name>Mukatova Irina</investigator_full_name>
    <investigator_title>PhD. Professor of medicine. Head of deparment pulmonology</investigator_title>
  </responsible_party>
  <keyword>Vibroacustic therapy</keyword>
  <keyword>COVID19</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

